GlassScriptPhysician profile
Carlos Rivera Lopez
NPI 1124575436
$4,076.62
in general payments reported to CMS, 2019-2025
15 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2021: $121 · 2022: $638 · 2023: $2,383 · 2024: $534 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,552 · Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,552.46 |
| Food and Beverage | $1,512.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,730.32 | 2021-2024 | Greenlight Xps, Lumenis Pulse 120h, Rezum Generator |
| Astellas Pharma US INC | $201.28 | 2021-2023 | Xtandi |
| Medtronic, INC. | $193.40 | 2019-2023 | Interstim |
| Urogen Pharma, INC. | $162.07 | 2022-2023 | Jelmyto |
| Teleflex LLC | $128.13 | 2024 | Urolift |
| Merck Sharp & Dohme LLC | $120.00 | 2024 | Keytruda |
| Janssen Pharmaceuticals, INC | $113.48 | 2024 | Talvey, Darzalex, Erleada |
| Olympus Latin America, INC. | $98.63 | 2019 | |
| Profound Medical Corp. | $98.53 | 2025 | Tulsa-Pro |
| Janssen Biotech, INC. | $61.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.97 | 2025 | Lokelma |
| Genentech USA, INC. | $46.40 | 2022-2023 | Lunsumio, Polivy, Gazyva |
| Emd Serono, INC. | $33.33 | 2024 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $23.44 | 2024 | Opdivo |
| Pbg Puerto Rico LLC | $16.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Rivera Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.